Plasma Concentration of Human Brain Natriuretic Peptide in Patients on Hemodialysis

Ishizaka, Yuko; Yamamoto, Yoshitaka; Fukunaga, Takashi; Yokota, Naoto; Kida, Osamu; Kïtamura, Kazuo; Kangawa, Kenji; Minamino, Naoto; Matsuo, Hisayuki; Eto, Tanenao

doi:10.1016/s0272-6386(12)80903-6

Cited by 65 publications

(59 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BNP predicted mortality in dialysis patients without heart failure, and the prognostic value of BNP was independent of LVMI and LVEF (27). Furthermore, changes in BNP levels with hemodialysis correlated with extracellular fluid retention and volume change independent of LV function (43)(44)(45)(46). However, there are as yet no data on this aspect in PD patients.…”

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro-Brain Natriuretic Peptide

Wang

Lam²,

Yu³

et al. 2007

Journal of the American Society of Nephrology

144

134

View full text Add to dashboard Cite

This study was performed to determine whether the N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is a useful biomarker in predicting cardiovascular congestion, mortality, and cardiovascular death and event in chronic peritoneal dialysis (PD) patients. A prospective cohort study was conducted in 230 chronic PD patients in a dialysis unit of a university teaching hospital. Serum NT-pro-BNP was measured at baseline together with echocardiography and dialysis indices. Each patient was followed for 3 yr from the day of enrollment or until death. Time to develop first episode of cardiovascular congestion and other cardiovascular event and time to mortality and cardiovascular death were studied in relation to NT-pro-BNP. NT-pro-BNP showed the strongest correlation with residual GFR, followed by left ventricular ejection fraction and left ventricular mass index. In the univariate Cox regression model, NT-pro-BNP was a significant predictor of cardiovascular congestion, mortality, and cardiovascular death and event. In the fully adjusted multivariable Cox regression analysis that included residual GFR, left ventricular ejection fraction, and left ventricular mass index, the hazard ratios for cardiovascular congestion, mortality, composite end point of mortality and cardiovascular congestion, and cardiovascular death and event for patients of the fourth quartile were 4.25 (95% confidence interval [CI] 1.56 to 11.62; P ‫؍‬ 0.005), 4.97 (95% CI 1.35 to 18.28; P ‫؍‬ 0.016), 5.03 (95% CI 2.07 to 12.26; P < 0.001), 7.50 (95% CI 1.36 to 41.39; P ‫؍‬ 0.021), and 9.10 (95% CI 2.46 to 33.67; P ‫؍‬ 0.001), respectively, compared with the first quartile. These data showed that NT-pro-BNP is an important risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic PD patients and adds important prognostic information beyond that contributed by left ventricular hypertrophy, systolic dysfunction, and other conventional risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro-Brain Natriuretic Peptide

Wang

Lam²,

Yu³

et al. 2007

Journal of the American Society of Nephrology

144

134

View full text Add to dashboard Cite

show abstract

“…12, 27 Akiba et al 40 analyzed the relation between BNP and creatinine in a group of healthy controls (creatinine 0.5-1.2 mg/dl; BNP 12722 pg/ml), in patients with isolated chronic glomerulonephritis (creatinine 41.2 mg/dl; BNP 17723 pg/ml), and in patients on dialysis (BNP 91793 pg/ml). These authors concluded that BNP is not directly related to renal failure but probably to the hemodynamic stress of dialysis.…”

Section: Ventricular Natriuretic Peptide (Bnp) In Heart Transplantationmentioning

confidence: 99%

“…14,18,19 In addition, an increase in serum BNP concentrations proportional to the clinical severity of heart failure has been demonstrated. 20 High BNP values have also been found in patients with high blood pressure, ventricular hypertrophy, ischemic heart disease and other heart diseases, [21][22][23][24][25][26] renal failure subjected to hemodialysis, 12,27 and in heart transplantation. [28][29][30] The utility of BNP in the diagnosis of heart transplant rejection has not been thoroughly investigated to date; the studies were generally limited to few cases with a short follow-up duration and sometimes contradictory results.…”

mentioning

confidence: 99%

Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and hemodynamic measures

et al. 2003

View full text Add to dashboard Cite

A prospective study of 81 heart transplant (HT) patients was carried out in order to evaluate the evolution of brain natriuretic peptide (BNP) levels in HT patients and compare them with the degree of rejection as determined by endomyocardial biopsy. All patients were subjected to endomyocardial biopsy (532), and determination of BNP and creatinine levels as well as hemodynamic parameters. A control group of 36 volunteers was included. BNP values were significantly greater in HT patients than in healthy volunteers. In the first 3 months, BNP levels in patients with treatable rejection were significantly greater than in patients without graft rejection, although evident overlapping was observed in both distributions and discriminatory potential was low. After the third month, BNP values were similar in patients with and without rejection. Creatinine levels were observed to increase over time after transplantation, but no correlation was observed between the creatinine and BNP levels. A significant positive correlation was observed between BNP and right ventricle and pulmonary arterial pressures.

show abstract

“…B-Type natriuretic peptides (BNPs) and renal function have been shown to be prognostic indicators of survival in patients with congestive heart failure (CHF) (5,6,22,23 ). Renal function correlates weakly with the measurement of BNP and may influence the cutoff concentration used for the final diagnosis of CHF (24 ).…”

mentioning

confidence: 99%

Multi-Biomarker Risk Stratification of N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein, and Cardiac Troponin T and I in End-Stage Renal Disease for All-Cause Death

et al. 2004

View full text Add to dashboard Cite

Background:In patients with end-stage renal disease (ESRD), the ability of single and multiple biomarker monitoring to predict adverse outcomes has not been well established. This study determined the prognostic value of multiple biomarkers for all-cause death over 2 years in 399 ESRD patients. Methods:The risk of all-cause death was determined by use of multiple biomarkers based on concentrations for a reference population (normal) and cutoffs based on tertile distributions in the ESRD group. Biomarkers studied included N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP; Dade Behring and Roche assays), and cardiac troponin T (cTnT; Roche) and I (cTnI; Dade Behring and Beckman Coulter assays). Relative risks of death were estimated and survival curves computed. Results: A total of 101 deaths occurred during 594 patient-years of follow-up. Increased NT-proBNP concentrations were not predictive of death on the basis of the normal cutoffs. However, tertile analysis of NTproBNP was significantly predictive of death and had a ROC area under the curve equivalent to or better than any of the other biomarkers. Biomarkers independently predictive of survival were hsCRP (P <0.001, either assay), cTnT (P <0.05), and cTnI (Dade, P <0.05). Twoyear mortality rates were 6% (n ‫؍‬ 45) with normal hsCRP, cTnI, and cTnT concentrations; 19% (n ‫؍‬ 173) with increased hsCRP or cTnT and normal cTnI; 44%

show abstract

Plasma Concentration of Human Brain Natriuretic Peptide in Patients on Hemodialysis

Cited by 65 publications

References 34 publications

N-Terminal Pro-Brain Natriuretic Peptide

N-Terminal Pro-Brain Natriuretic Peptide

Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and hemodynamic measures

Multi-Biomarker Risk Stratification of N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein, and Cardiac Troponin T and I in End-Stage Renal Disease for All-Cause Death

Contact Info

Product

Resources

About